Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
Lv D, Pal P, Liu X, Jia Y, Thummuri D, Zhang P, Hu W, Pei J, Zhang Q, Zhou S, Khan S, Zhang X, Hua N, Yang Q, Arango S, Zhang W, Nayak D, Olsen SK, Weintraub ST, Hromas R, Konopleva M, Yuan Y, Zheng G, Zhou D. Lv D, et al. Among authors: hromas r. Nat Commun. 2021 Nov 25;12(1):6896. doi: 10.1038/s41467-021-27210-x. Nat Commun. 2021. PMID: 34824248 Free PMC article.
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.
Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, Pei J, Zhang W, Sharma A, McCurdy CR, Kuruvilla VM, Baran N, Ferrando AA, Kim YM, Rogojina A, Houghton PJ, Huang G, Hromas R, Konopleva M, Zheng G, Zhou D. Khan S, et al. Among authors: hromas r. Nat Med. 2019 Dec;25(12):1938-1947. doi: 10.1038/s41591-019-0668-z. Epub 2019 Dec 2. Nat Med. 2019. PMID: 31792461 Free PMC article.
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216.
Thummuri D, Khan S, Underwood PW, Zhang P, Wiegand J, Zhang X, Budamagunta V, Sobh A, Tagmount A, Loguinov A, Riner AN, Akki AS, Williamson E, Hromas R, Vulpe CD, Zheng G, Trevino JG, Zhou D. Thummuri D, et al. Among authors: hromas r. Mol Cancer Ther. 2022 Jan;21(1):184-192. doi: 10.1158/1535-7163.MCT-21-0474. Epub 2021 Oct 19. Mol Cancer Ther. 2022. PMID: 34667112 Free PMC article.
TATDN2 resolution of R-loops is required for survival of BRCA1-mutant cancer cells.
Jaiswal AS, Dutta A, Srinivasan G, Yuan Y, Zhou D, Shaheen M, Sadideen DT, Kirby A, Williamson EA, Gupta YK, Olsen SK, Xu M, Loranc E, Mukhopadhyay P, Pertsemlidis A, Bishop AJR, Sung P, Nickoloff JA, Hromas R. Jaiswal AS, et al. Among authors: hromas r. Nucleic Acids Res. 2023 Dec 11;51(22):12224-12241. doi: 10.1093/nar/gkad952. Nucleic Acids Res. 2023. PMID: 37953292 Free PMC article.
PARP1 is required for chromosomal translocations.
Wray J, Williamson EA, Singh SB, Wu Y, Cogle CR, Weinstock DM, Zhang Y, Lee SH, Zhou D, Shao L, Hauer-Jensen M, Pathak R, Klimek V, Nickoloff JA, Hromas R. Wray J, et al. Among authors: hromas r. Blood. 2013 May 23;121(21):4359-65. doi: 10.1182/blood-2012-10-460527. Epub 2013 Apr 8. Blood. 2013. PMID: 23568489 Free PMC article.
211 results